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Bronchopulmonary dysplasia is a major issue affecting morbidity and mortality of
surviving premature babies. Preterm newborns are particularly susceptible to oxidative
stress and infants with bronchopulmonary dysplasia have a typical oxidation pattern
in the early stages of this disease, suggesting the important role of oxidative stress in
its pathogenesis. Bronchopulmonary dysplasia is a complex disease where knowledge
advances as new investigative tools become available. The explosion of the “omics”
disciplines has recently affected BPD research. This review focuses on the new evidence
coming from microbiomics, metabolomics and proteomics in relation to oxidative stress
and pathogenesis of bronchopulmonary dysplasia. Since the pathogenesis is not yet
completely understood, information gained in this regard would be important for planning
an efficacious prevention and treatment strategy for the future.
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OXIDATIVE STRESS AND BRONCHOPULMONARY DYSPLASIA:
AN OVERVIEW
Preterm newborns are particularly susceptible to oxidative stress (OS), as a consequence of
different factors, such as exposure to high levels of oxygen, inflammation and inadequate
defenses to oxidative injury (1). In 1998, Saugstad coined the term “oxygen radical disease of
Neonatology” to indicate several pathologic conditions of neonate where OS plays a crucial role,
including bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), periventricular
leukomalacia and intraventricular hemorrhage (IVH) (2, 3). Despite the improvements in the
management of BPD in Neonatal Intensive Care Units, this illness is still considered the most
common pulmonary disease in infants born preterm, especially in those weighting <1,500 g at
birth (4, 5). Moreover, BPD represents the most important respiratory long-term issue affecting
the respiratory function of surviving premature infant along entire life.
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The first report by Northway in 1967 focused on the
inflammation in the lungs of neonates with prolonged oxygen
exposure. Since then, the pathology of BPD has completely
changed. A “new BPD” has been characterized with less
in number and larger alveoli and abnormal lung vascular
remodeling. The “new BPD” affects mostly very preterm infants
with an incidence around 21–47% in the babies weighing
between 501 and 1,500 g at birth (6). These infants are
born with lungs in the saccular stage when alveoli are just
beginning to differentiate; at this early stage of lung development
both prenatal determinants (e.g., maternal chorioamnionitis)
and neonatal factors such as resuscitation, oxygen exposure,
infection, mechanical ventilation and patent duct arteriosus,
interfere with alveolar and vascular lung formation leading to
a general developmental arrest. Inflammation is the common
denominator of these prenatal and neonatal interferences and
the production of free oxygen radicals has a predominant
role (1, 6–9).
OS results each time free oxygen radicals production exceeds
the capability of antioxidant enzymes to neutralize them (8);
this condition is very common in premature babies because
of the immaturity of antioxidant system typical of this early
age of life. Lung inflammation develops when pro-inflammatory
cytokines (tumor necrosis factor α, interleukin-1 or IL-1, IL-6,
IL-8) are released in response to prenatal and neonatal triggering
factors (chorioamnionitis, infection, mechanical ventilation etc.).
These mediators recruit and activate granulocytes to release
free oxygen radicals causing endothelial peroxidation, increased
vascular permeability, interstitial, alveolar and airway oedema,
especially in presence of high oxygen concentration (8). Infants
with BPD have an oxidation pattern that is different from those
who do not develop BPD. Several authors found high levels of OS
markers, such as lipid or protein oxidation products, in the early
stages of this disease, suggesting the important role of OS in its
pathogenesis. These markers have been detected in different body
fluids few hours or in the first weeks after birth in newborns that
subsequently developed BPD (10–17). This statement implies
that OS may start in the antenatal period, and every antioxidant
therapy given after birth might not be sufficient to prevent this
disease (18).
Also, the OS mediates the intracellular modification of
target genes expression that regulate lung development
with mechanisms not yet completely understood (9). Yet, a
comprehensive understanding of BPD pathophysiology is crucial
to design both preventive and therapeutic strategies.
An interesting recent study “in vivo” in a cohort of 451
preterm infants addresses the association of a polymorphism
related to the NADPH family with oxidative stress-related
complications of prematurity as BPD, RDS and ROP. This study
points out that genetic polymorphism may cause variable clinical
response to oxidative stress induced damage in preterm infants
(19) and explains that each preterm neonate has a different
susceptibility to OS related diseases.
In recent years, a fundamental role in lung development
has been attributed to lipofibroblasts, differentiated lung
mesenchymal cells containing lipid droplets. These cells are
responsible for alveolar growth, differentiation, homeostasis,
surfactant production and repair. Experimental evidences shows
that hyperoxia determines the differentiation of lipofibroblasts
into myofibroblasts. Since the latter are unable to guarantee
normal pulmonary epithelial cell growth and differentiation,
a general arrest of alveolarization typical of BPD results
(20). Interestingly, the nuclear transcription factor PPARy
(peroxisome proliferator-activated receptor y) which has an
important role in alveolar homeostasis and injury repair,
seems to be related to myofibroblasts differentiation caused
by oxidative stress. Curcumin, a known PPARy agonist, has
been shown to inhibit myofibroblasts differentiation involved
in BPD pathogenesis in an animal model of hyperoxia induced
lung injury; in a neonatal rat model, curcumin enhanced lung
maturation and blocked hyperoxia induced lung injury (9).
Beta-catenin is another target of oxidative stress recently
studied, that may be relevant for a therapeutic approach to
BPD. Beta-catenin is a component of the cytoskeleton and plays
a role in regulating transcription of genes responsible for cell
proliferation, differentiation and apoptosis (21).
Beta-catenin activity has a peak during the canalicular stage
and decreases normally in the saccular stage. Examination of
infants who died with BPD showed the persistence of β-catenin
at term that should not be found in normally developed lungs.
Hyperoxia has been showed to increase β-catenin and target
gene expression in the lungs of neonatal rats; inhibition of β-
catenin target gene expression prevents hyperoxia-induced arrest
of alveolarization. Specifically, connective tissue growth factor
(CTGF) and fibronectin are β-catenin target genes that play
an important role in extracellular matrix deposition and in
vascular remodeling associated to new BPD as a consequence of
different factors, such as exposure to high oxygen concentration.
Treatment with ICG001 (an inhibitor of β-catenin) significantly
decreased expression of fibronectin and CTGF under hyperoxia
in rat pups and reduced alveolar impairment associated to
hyperoxia (21–23).
Hyperoxia has indeed multiple impacts on surfactant too.
It can increase surfactant proteins SP-A, SP-B, and SP-C, but
at the same time hyperoxia causes loss of the immune defense
and surfactant powers of the protein SP-A and may have an
impact on the enzyme glycerol-3 phosphate acyltransferase, thus
reducing the production of surfactant phospholipids (10) and
potentially prolonging need of ventilator support and the risk to
develop BPD.
BPD is a complex disease where knowledge advances as new
investigative tools become available. The explosion of the “omics”
disciplines has recently affected BPD research (Figure 1). The
following paragraphs focus on the new evidence coming from
microbiomics, metabolomics and proteomics.
MICROBIOMICS AND BPD
Microbiomics is a field of research in which all the
microorganisms of a given environment, called microbiome, are
analyzed to study the potential role that such microorganisms
have in diseases. An emerging field of interest is the lung
microbiome and its correlation with the pathogenesis of BPD.
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FIGURE 1 | Role of oxidative stress in BPD pathogenesis and contribution of “omic sciences” to identify preterm infants at risk of BPD and to demonstrate the
rationale of therapies to reduce oxidative stress and potentially prevent BPD.
It has been reported that there are 10–100 bacterial cells per
1,000 human cells in the upper and lower airways (24). The
lung microbiome changes during the first weeks of postnatal
life. In particular, there are several factors related to preterm
birth that can alter its development (25). Chorioamnionitis or a
transplacental infection can activate an inflammatory state that
acts as a trigger for the development of BPD (26). Furthermore,
the use of antibiotics both in utero and after birth has been
associated with an increased incidence of BPD (27, 28). Other
factors included are the use of ventilatory assistance devices,
enteral nutrition, the occurrence of sepsis and the concomitant
development of the intestinal microbiome (25). There is indeed
an association (gut-lung axis) between the development of
gut and lung microbiome (29). Intestinal dysbiosis has been
counted among the causes of necrotizing enterocolitis, and if
this process of dysbiosis occurs also at pulmonary level, it could
trigger the inflammatory process underlying BPD. This could be
explained by the presence of commensal bacteria in the lungs
that are involved in the formation of the immune system; if such
commensal bacteria are eliminated or damaged by the factors
reported above, an abnormal inflammatory response responsible
for the pathogenesis of BPD may take place (30).
Wagner et al demonstrated that there is a higher microbiome
turnover with age in infants with a more severe BPD.
In particular, the concentration of Staphylococcus spp. is
lower in the first days of life, while there is an higher
concentration of Ureaplasma spp. This suggests a possible
role of microbiome in the delineation of BPD severity (31).
Similarly, Imamura et al detected a higher presence of
Corynebacterium spp. in infants with severe BPD, especially
in those treated with longer invasive ventilation (32). Several
authors tried to define lung microbiome in preterm infants
using endotracheal aspirates (ETA) samples (33). Their findings
indicate that lungs of preterm newborns are already colonized
at birth with species as Acinetobacter spp. (34); therefore
placenta and amniotic fluid are not sterile in such babies
and contribute to the colonization of fetal tissues already
in utero (24, 35).
Payne et al.(36) presented an observational study about 55
preterm infants born weighing <1,300 grams in which ETA and
nasogastric aspirates (NGA) were examined with a combined use
of denaturing gradient gel electrophoresis (DGGE) and species-
specific PCR. DGGE showed a wide range of bacterial species in
59% of NGA and ETA samples, many of them associated with
preterm labor. Species-specific PCR found Mycoplasma hominis
in 25% of NGA and 11% of ETA samples. With regard to
patients who survived up to 36 weeks, the authors didn’t find an
association between Ureaplasma spp. in NGA and BPD, which
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can be related to sampling errors, even if these species are highly
detected in ETA samples at 24 h of age (36).
About the role of the lung microbiome in the maturation of
the immune system (37), this may act through the production of
metabolites, as tryptophan catabolites, which are agonist of the
aryl hydrocarbon receptor (AhR) that regulates the production
of antioxidant enzymes (38, 39).
In humans, AhR is highly expressed in the lungs (40) and
it exerts its anti-inflammatory effects in part by positively
regulating the expression of nuclear RelB (41–44), which in turn
inhibits inflammatory processes by modulating the expression of
several chemokines and cytokines (45–49).
Therefore, a dysfunction in AhR can result in an increase
in OS injury (50). In particular, Zhang et al showed that
AhR-deficient fetal human pulmonary microvascular endothelial
cells (HPMEC) are associated with an increased production of
hyperoxia-induced reactive oxygen species (ROS), a heightened
inflammatory state, a decrease in antioxidant enzimes and in
ReIB activation compared to AhR-sufficient HPMEC (50).
Interestingly, Lactobacilli have the ability to metabolize
triptophan into AhR agonists, suggesting an important
modulatory role of these bacteria on the OS (51, 52). Segal et al
revealed in their study the role of the macrolide azithromycin
in increasing levels of tryptophan catabolites in ETAs of
emphysematous lungs, thus reducing the production of
proinflammatory cytokines (51). Moreover, a cohort study
made by Lal et al. found that the number of Lactobacilli in
the lung microbiome of preterms who developed BPD was
significantly lower than infants who did not develop BPD,
and this low concentration was evident in preterm newborns
whose mother suffered from chorioamnionitis (53). More
recently, the same authors highlighted the relationship between
microbiomics and metabolomics by analyzing the metagenome
of the microbiome and the metabolome at birth in the lungs
of extremely low birth weight (ELBW) infants. They found an
increased number of metabolites involved in sexual hormones
synthesis and in fatty acid activation in the airway metabolome
of BPD-predisposed infants, compared to BPD-resistant infants.
The authors concluded that the lung microbiome of ELBW
infants affect metabolome, and that sexual dimorphism could
alter the risk of BPD (54).
Moreover, a study in mice reported that the injection of
Lactobacilli into the lungs could improve alveolar development
(55). All of these findings indicate a potential role of the
microbiome in reducing the OS correlated to BPD (in fact, the
administration of Lactobacilli or the use of azithromycin could
be potential tools in the prevention or in the treatment of BPD).
This can be explained by their capacity in reducing macrophage
production of proinflammatory citokines, which are responsible
to amplify OS (56). In the same direction, a recent study on
omeprazole demonstrated that this pump inhibitor can induce
Cytochrome P4501A1 (CYP1A1) that has protective properties
against hyperoxia, possibly through the activation of the
AhR signaling.
Omeprazole is not considered a typical AhR-ligand (57). It
is assumed that it may reduce the interaction forces which hold
AhR complex in a silencing state. This action could turn AhR into
a DNA binding form, which if accumulated in the nucleus, could
activate the transcription of CYP1A1 (58).
Therefore, omeprazole could be another potential way to
prevent BPD in the prenatal and postnatal period (59).
METABOLOMICS AND BPD
Metabolomics is defined as “the quantitative measure of the
multiparametric dynamic metabolic response of the living
systems to physiopathological stimuli or genetics modifications”
(60). This “omics” science studies all the final products of
biochemical reactions, endogenous and exogenous metabolites,
occurring in body tissues and fluids, in order to define the
biochemical phenotype of an individual, as a “photograph” of
the status of an organism in a specific time of his life (61–63).
This aspect can be applied to better understand the predictability,
the diagnosis and the treatment of several diseases, for instance
BPD, for which early identification, as previously suggested,
could be essential to reduce its severity and complications (64–
67). Metabolomics uses two different analytical techniques, as
Proton Nuclear Magnetic Resonance (1 H-NMR) Spectroscopy
and Liquid Chromatography or Gas Chromatography coupled
to Mass Spectrometry (LC/GC-MS), for its purposes. The
process develops in two phases; first is the recognition of
metabolites on the basis of their characteristic structure, followed
by a multivariate statistical analysis (68). Metabolomics can
be divided in two different approaches, called untargeted
and targeted metabolomics. Untargeted metabolomics is a
comprehensive analysis of all measurable analytes in a sample,
including chemical unknowns, while targeted metabolomics is
the measurement of a defined set of metabolites in a biological
sample. Both the approaches have advantages and disadvantages;
untargeted metabolomics takes time to process all the data and
it finds difficulties in identifying and defining small molecules, in
addition to the fact that it can be subject to bias, features that are
reduced through the use of targeted metabolomics (69).
In 2014V. Fanos and colleagues published the first study
using this two-step process to compare urine samples collected
at birth of neonates <30 weeks who later developed BPD with
a control healthy group. In the BPD group, they detected some
metabolites absent in the control group, as lactate, taurine,
and Trimethylamine N-oxide (TMAO), with an increased
myoinositol and a decreased gluconate (69). Similar results were
subsequently reported in 2016 by Baraldi et al. who examined 32
amniotic fluid samples using the same tools (70). Considering
the analyzed metabolites, myinositol appears to be involved in
lung maturation during antenatal life (71). The increase of the
urinary lactate, on the other hand, seems to be related to the
activation of anaerobic glycolysis in response to hypoxia. With
regard to taurine and TMAO, these two metabolites are involved
in osmoregulation, membrane stabilization and in renal cell
cycle. Moreover, taurine plays other important roles in calcium
homeostasis, in detoxification and in nerve cell activity. TMAO
is also known as a marker of renal medullary damage (72, 73)
and of papillar dysfunction (74). The authors concluded that BPD
could be the sum of a dysfunctional development; consequently,
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it can be considered a congenital disease (75). A recent study
published by the same group (76) examined urine samples at 7
days of life of 18 preterm newborns; seven of them subsequently
developed BPD. The metabolites that differ in the neonates who
developed BPD compared who did not, were represented by
alanine, betaine, trimethylamine-N-oxide, lactate, and glycine.
What is interesting is that glycine levels in BPD group were lower
than in controls. Glycine is involved in glutathione synthesis,
which has an important antioxidant role (77). It can also inhibit
nuclear factor-kappa (NF-kB) activation and it can avoid the
expression of inducible nitric oxide synthetase (iNOS) (78).
Therefore, reduced levels of glycine and lactate in the BPD group
could be representative of a situation of OS.
Therefore, BPD can be considered the result of a series of
prenatal developmental deregulations, supporting the idea that
part of the injury starts before birth (24). Consequentely, early
detection of such mechanism may help to develop a targeted
approach for increasing the chances of recovery of these patients.
In this respect, metabolomics could be a useful tool to detect a
metabolic “fingerprint” able to identify, during the intrauterine
life or at birth, which newborns will later develop BPD. This
could help physicians to implement its management, especially
avoiding oxidative injuries as early as possible. Further studies are
needed to better understand the correlation between the above
findings and BPD, especially in order to find a list of the key
metabolites diagnostic for this disease.
PROTEOMICS, TRANSCRIPTOMICS AND
BPD
Proteomics is the large-scale analysis of the proteome, the entire
set of proteins produced or modified by an organism in analogy
with genomics, the study of the genome. One of the positive
implication of proteomics is to identify proteins implicated in
diseases and offer targets to researchers to develop potential
preventive strategy and treatments. Only 4% of proteomic studies
aimed at lung injury and disease have focused on pediatric lung
disease (79). As BPD is a multifactorial disease and involves
different molecular pathways, the proteomic analysis is very
important because it may help to study the networks of proteins
implicated in its pathogenesis and their interactions.
Actually, no molecules are able to definitely predict the
predisposition to develop BPD before its clinical onset. Several
studies underlined an imbalance between proteases and anti-
proteases playing a central role in the pathogenesis of BPD.
An interesting study in preterm infants has been conducted by
Magagnotti et al. aimed to describe the networks of proteins
involved in the disease and the modulation of protein function
(80). The authors showed a proteomic analysis of ETAfrom
infants with BPD and controls, using mass spectroscopy. The
results were further validated by western blotting. The authors
found a clear differential expression in the proteome of the
23–25 weeks gestational age (GA) group respect to the 26–
29 weeks GA group. Surfactant protein-A2, annexin-3, calcium
and integrin binding protein-1, leukocyte elastase inhibitor,
chloride intracellular channel protein 1 and calcyphosine were
differentially expressed in severe BPD patients with lower GA
(23–25 weeks gestation). In relation to the OS, leukocyte elastase
inhibitor was downregulated in severe BPD patients. A major
limitation of this study was the small sample size.
More recently, Shrestha et al. (81), combined transcriptomic
and proteomic analysis to further elucidate the molecular
mechanisms underlying BPD. They conducted a study using
neonatal C57BL6J wild-type mice, with the aim to test the
hypothesis that hyperoxia exposure during the saccular and
alveolar development phase alters the level of genes and
proteins necessary for optimal lung development and repair.
The authors performed a correlation analysis between the
proteinomic and transcriptomic data and the results showed
that hyperoxia exposure dysregulated the expression of 344
genes and 21 proteins. Interestingly, hyperoxia downregulated
genes were involved in maturation of lung tissues and neuronal
tissue too. Oxidoreductase activity, apoptosis, plasma membrane
integrity, organ development, angiogenesis, cell proliferation and
mitophagy have been identified as the predominant processes
affected by hyperoxia.
A proteolytic enzyme having a potential role in the
pathogenesis of BPD is alpha-1 antitrypsin (AAT). AAT is a
well characterized anti-proteases inhibitor of Neutrophil Elastase
(NE). AAT proteinases degradation and inactivation lead to
increased NE activity. AAT has significant anti-inflammatory
properties leading also to its potential therapeutic use in several
important diseases (82). Recently, it has been demonstrated
the presence of sufficient AAT elastase inhibitory activity in
the airways of a new BPD baboon model but not in the
severe BPD one (83). The same authors showed an increase
of AAT elastase inhibitory activity in “severe BPD” baboons
following the treatment with a catalytic antioxidant, suggesting
that prevention of the oxidative inactivation of AAT may be one
of the mechanisms by which antioxidant therapy improves the
pulmonary outcomes in animal models of “severe BPD.”
Taggart C. et al. (84) showed as the inactivation of AAT by
oxidation of either methionine 351 or 358 provides a mechanism
for activity regulation at sites of inflammation. On the basis of
these studies, it could be hypothesized that neonates who will
develop a severe new BPD form, could benefit from an increase
of the AAT antiprotease activity by areosolic or endovenous
administration or by treatment with a catalytic antioxidant.
In neonates with respiratory distress syndrome treated with
surfactant, the intravenous administration of AAT has been
tested (85), but a reduction in the incidence of pulmonary
hemorrhage rather than BPD was obtained. Improving research
in this field could achieve a strategy to prevent BPD.
POTENTIAL THERAPIES FOR OS
PREDISPOSING TO BPD
Studies are in progress on curcumin (PPARy agonist), inhibitor of
β-catenin, treatment with ICG001, lactobacilli and azithromicine
as reported above.
A well-known drug, caffeine, demonstrated a significant
clinical role in reducing BPD rates when used as an early
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treatment from the first 3 days of life. As a possible basic
science explanation of this clinical finding, a recent animal study
showed that caffeine ameliorates hyperoxia induced lung injury
in rat pups trough attenuation of endoplasmic reticulum stress.
Caffeine also attenuated the hyperoxia induced activation of
cyclooxygenase-2 and markers of apoptosis as caspase-12 and
BCl2/Bax that play a central role in endoplasmic reticulum stress
mediated apoptosis (86).
Also, the phosphodiesterase inhibitor pentoxifylline, has been
shown in an animal model of hyperoxia-induced lung -injury to
increase lung antioxidant enzymes such as superoxide dismutase,
catalase and glutathione peroxidase (87). This ability to increase
lung antioxidant enzymes may be particularly relevant for
premature babies that are prone to oxidative stress damage
because of the low activity of antioxidant system in early stage of
life. The development of drugs with antioxidant effect may offer
in the future an important preventive strategy for BPD.
Another future strategy to prevent/treat BPD is the use of
stem cell therapy based on stem cell potential in injury repair. In
an animal model of hyperoxia-induced lung injury, a protective
role of stem cells has been shown attributable to capacity of
such cells to decrease inflammation, repair tissue and reduce
apoptosis (88). As reported by Lesage and Th’ebaud recently
(89), mesenchymal stromal cells (MSCs) present in perinatal
tissue (placenta, cord, and cord blood) and administrated in the
airway or intravenously, prevents oxygen-induced lung injury
in neonatal rats and mice. Human cord blood and cord tissue-
derived MSCs injected intratracheally or intravenously were also
capable of preventing oxygen-induced impairment in alveolar
and lung vascular growth, as well as preserving lung. MSCs
seem to act by means of transferring cellular organelles such as
mitochondria and secretion of bioactive molecules that modulate
the repair process in the injured cells and promote lung growth.
MSCs also release anti-inflammatory factors such as tumor
necrosis factor-stimulated gene-6 and factors decreasing OS such
as stanniocalcin-1. The therapeutic effects of MSCs on BPD seem
related indeed to their paracrine effects on lung tissue, secretome,
and represents a promising therapeutic approach that needs to be
further explored in the future to treat BPD.
CONCLUSION
BPD is the most common and serious chronic lung disease of
premature infants that changed during the decades in clinical,
anatomical and physiophatological features. To date, recent
studies demonstrated the pivotal role of OS in influencing gene
expression responsible for arrest of alveolarization and abnormal
lung vascular development typical of the “new BPD.”
A definitive therapy for BPD has not been accomplished,
yet. Understanding the molecular mechanisms that drive the
premature lungs to the “new BPD” is the only way to achieve
therapies based on a pathogenic approach, possibly to reach a
definitive therapy.
Recent studies showed that some molecular mechanisms
begin very early during fetal life and at birth and preterm
babies have genetically determined different susceptibility to
respond to OS. Microbiomics shows that factors interfering with
lung microbiome in preterm neonates may trigger inflammatory
process and the OS injury leading to BPD; indeed, the use of
lactobacilli, azithromycin and omeprazole are drugs potentially
protective against OS injury in preterm neonates. Metabolomics
shows that preterm neonates subsequently developing BPD have
a different metabolic response since birth compared with those
not developing BPD such us reduction of glycine and increase
of lactate that are related to OS. These findings support the idea
that part of the oxidative injury starts before birth for neonates
who will develop BPD. Metabolomics and microbiomics in the
future could be used to detect a “fingerprint” able to identify at
birth preterm neonates at risk of developing BPD. Early detection
of such neonates may individualize neonatal management to
prevent and treat OS. Proteomics shows that enzymes protecting
against OS are down regulated in BPD infants, thus antioxidant
therapy may be a potential tool to treat them.
In conclusion, with the help of new techniques as
metabolomics, microbiomics and proteomics we may be
able in the future to screen at birth the preterm new-borns
more susceptible to BPD and potentially treat them in an
individualized fashion with hopefully promising new therapy
to prevent or attenuate BPD.
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